|
 |
Sign up and receive information about Novartis clinical
trials in your health-related areas of interest. For U.S.
residents only. |
|
|
 |
|
|
|
As a resource to our visitors, Novartis provides the following links to other web sites. We try to carefully choose websites that we believe are useful and meet our standards. However, Novartis does not control, endorse, promote, or have any affiliation with any other website unless it is expressly stated. Novartis is not responsible for the content, accuracy, or any other aspect of the information contained on such linked sites.
ATTRACT Clinical Research Program for Lung Cancer
|
Novartis Oncology is conducting a clinical research program called ATTRACT which is designed to ASA404 in patients with non-small cell lung cancer. To learn more about this research and to see if you may qualify to participate, click on the link below.
|
|
www.LungCancerStudyInfo.com
|
Aggressive Systemic Mastocytosis (ASM) Clinical Trial
|
Novartis Oncology is conducting clinical research to determine if the study drug midostaurin is safe and effective in people who have either aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL). If you are between the ages of 18 and 70, and have been diagnosed with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL), you may be eligible to participate in this trial. To learn more about this research click on the link below.
|
|
www.systemicmastocytosistrial.com
|
Brain Metastases from Lung Cancer Research
|
Novartis Oncology is conducting a clinical research study to see if an investigational drug is an effective and safe treatment in people who have lung cancer that has spread to the brain. The study drug is called patupilone and it belongs to a new class of agents that works by preventing the growth of cancer cells through suppression of microtubule dynamics. If you or a family member or friend has been diagnosed with non-small cell lung cancer that has spread to the brain, and would like to see if you are eligible for this clinical trial, please click on the link below.
|
|
www.BrainCancerResearch.com
|
Breast Cancer Research
|
Novartis Oncology is currently conducting two clinical trials for Breast Cancer research. One trial is seeking post-menopausal women who have early breast cancer and recently underwent surgery. Candidates must be node-positive and hormone-receptor positive to be eligible for this trial. Another research study is seeking women who have had breast cancer that has spread to the bone and have been taking zoledronic acid (also called Zometa®) for at least one year. To learn more about this research and to see if you may qualify to participate, click on the link below.
|
|
www.BreastCancerResearchStudy.com
|
Cancer.gov
|
Explore this website from the National Cancer Institute to find information on a wide range of cancer topics as well as comprehensive descriptions of NCI research programs and clinical trials. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.
|
|
www.cancer.gov
|
Carcinoid Tumors Study
|
The purpose of this clinical trial is to compare the two drugs pasireotide LAR and octreotide LAR to find out which of these medicines gives the best relief from the diarrhea and flushing symptoms in participants with carcinoid disease who are not responding to other drugs.
|
|
www.carcinoidtumortrial.com
|
ClinicalTrials.gov
|
Novartis clinical trials are posted on ClinicalTrials.gov which is a website service provided by the U.S. National Institutes of Health (NIH). Click below to go directly to Novartis clinical trials posted on ClinicalTrials.gov.
|
|
www.ClinicalTrials.gov
|
Diabetes Clinical Research
|
If you have type 2 diabetes there are a few things you should know. Diabetics are two to four times more likely to develop heart disease, and approximately 1/3 will develop kidney disease. Additionally, diabetics with heart and kidney disease have higher mortality rates. A clinical study is under way to test the effectiveness of an investigational drug in reducing heart and kidney health problems in type 2 diabetics. Click the link below to learn more about this research and see if you may qualify to participate.
|
|
www.diabetesclinicalresearch.com
|
Diabetes Clinical Trials
|
Even if you’re exercising and eating right, you may not be in control of your diabetes, and adding medication may help. With Type 2 Diabetes, there is an insulin production imbalance or the body’s tissues become resistant to insulin. Insulin helps sugar (glucose) enter the cells where it is stored for energy. Novartis is currently conducting clinical research to study investigational medications for Type 2 Diabetes. If you would like to see if you qualify to participate, click on the link below.
|
|
www.DiabetesClinicalTrials.com
|
High Blood Pressure Research
|
Although some people with high blood pressure have symptoms, such as headaches or dizziness, most people with high blood pressure have no signs or symptoms at all. That is why it is so important to have your blood pressure checked regularly by your healthcare provider. Novartis is currently conducting a clinical trials studying the use of investigational medications for the treatment of people with high blood pressure (hypertension). If you would like to see if you qualify to participate, click on the link below.
|
|
www.BloodPressureResearch.com
|
Medportica, powered by Novartis
|
Medportica, the Novartis site for US Healthcare professionals. With MedPortica you can quickly scan the most important medical news, latest journals updates, and trends as well as conveniently access, in one place, all the Novartis information you need. Click the below link to login or sign up for an account.
|
|
www.medportica.com
|
Novartis Trials is using Twitter!
|
Novartis posts newly listed trials on Twitter. To learn about these new trials, follow NovartisTrials on Twitter.
|
|
www.Twitter.com/NovartisTrials
|
Patient Assistance Now!
|
At Novartis, we believe that all Americans deserve access to quality health care, including prescription medicines, education about their disease or condition, and information on the medicines they take. We recognize that many patients today face obstacles that keep them from getting the Novartis medicines they need. We want to lend a helping hand. That is why Novartis is proud to offer Patient Assistance Now, an easy to use, comprehensive resource that allows you to access programs that may help you pay for your Novartis medicines. For more information, click the below link.
|
|
www.patientassistancenow.com
|
Pediatric Eczema Elective Registry (PEER)
|
The Pediatric Eczema Elective Registry (PEER) is an observational registry designed to monitor the long-term safety of Elidel®. If your child is between the ages of 2 - 17 years (at time of enrollment) and has used Elidel® cream for the treatment of eczema (atopic dermatitis), he or she may qualify to participate. Participation is easy, all you have to do is fill out 2 brief surveys a year. You will receive $25 after each completed survey is received during the observation period. Click the link below to learn more about PEER or call the following toll-free number for more information: 1-877-711-7337 (PEER).
|
|
www.ChildrensEczemaRegistry.com
|
Pillar-1 - Mantle Cell Lymphoma Clinical Trial
|
The Novartis clinical research study, Pillar-1, is investigating the drug RAD001 in patients with Mantle Cell Lymphoma (MCL). If you are 18 years or older and have been diagnosed with Mantle Cell Lymphoma you may be eligible to participate in this trial. To learn more about this research click on the link below.
|
|
www.pillar1clinicaltrials.com
|
Prostate Cancer Study
|
Prostate Cancer is the most common non-skin cancer in America. More than 234,000 men will be diagnosed with prostate cancer this year. If you have been diagnosed with Prostate Cancer, you may be eligible to participate in a new clinical trial being conducted by Novartis Oncology.
This study is designed to evaluate the safety and effectiveness of a new investigational drug called patupilone, compared to an existing drug called docetaxel. If you or a friend or family member has a diagnosis of prostate cancer and have not yet received treatment for your cancer, you may be eligible to participate in this study. To learn more about this research click on the link below.
|
|
www.StudyForProstateCancer.com
|
RADIANT Clinical Research Program for Neuroendocrine Tumors
|
Novartis Oncology is conducting a clinical research program called RADIANT which is designed to evaluate an investigational drug called RAD001 (everolimus) in patients with neuroendocrine tumors (islet cell cancer). To learn more about this research and to see if you may qualify to participate, click on the link below.
|
|
www.RadiantClinicalTrials.com
|
|
|
